Conclusion
NSCLC
NON-SMALL CELL LUNG CANCER, SOLID TUMORS, NSCLC
OMO-1 was tolerated at the dose of 250 mg BID and shows initial signs of MET inhibition and anti-tumor activity in METex14 mutated NSCLC patients.Targeted therapy for non-small cell lung cancer (NSCLC) with mesenchymal epithelial transition (MET) exon 14 skipping mutations and MET amplifications have improved outcomes. This study aimed to determine the safety and recommended phase II dose of OMO-1 to assess preliminary clinical efficacy in METex14-positive NSCLC and other MET-positive solid tumors.